An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus
By D. Lamarre, P. Anderson, M. Bailey, P. Beaulieu, G. Bolger, P. Bonneau, M. Bös, D. R. Cameron, M. Cartier, M. Cordingley and 18 more. Nature, 2003
883 citations recorded by the source corpus.
Subfields: Hepatology, Radiology, Nuclear Medicine and Imaging, Rheumatology
View Paper: https://www.semanticscholar.org/paper/288a751ba1dc72a7e6e1f9c50d42d75d5e3b94d6
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hepatology
In Radiology, Nuclear Medicine and Imaging
In Rheumatology
Citations in the corpus
- The specific and essential role of MAVS in antiviral innate immune responses. (2006, background): “…may partially explain why the HCV protease inhibitors are highly effective in rapidly reducing HCV viral loads in earlystage clinical trials (Lamarre et al., 2003); these inhibitors are expected to not only inhibit viral replication and assembly but also restore the host antiviral innate…”
- Genetic diversity and evolution of hepatitis C virus--15 years on. (2004, background): “In the future, this may be reproduced in HCV infections that are treated with the new generation of protease inhibitors (such as BILN 2061) and RNA polymerase inhibitors (Lamarre et al., 2003; Pause et al., 2003; Trozzi et al., 2003; Lu et al., 2004; Sarisky, 2004).”
- The exploration of macrocycles for drug discovery — an underexploited structural class (2008, background): “, which was advanced into clinical development before cardiac toxicity checked its progressio”
- Successful applications of computer aided drug discovery: moving drugs from concept to the clinic. (2010, background): “Given the established role for the NS3-NS4A serine protease in hepatitis C virus (HCV) replication, it is an ideal target for the development of new anti-HCV therapy [39,40].”
- Replication of hepatitis C virus (2007, background): “The NS3–4A serine protease has emerged as a prime target for the design of specific inhibitors as antiviral agent”
- Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. (2009, neutral): “Black 1 (1) 2 (2) 1 (1) 2 (2) Asian 3 (4) 2 (2) 0 4 ( 5 )”